DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Fitch Revises Bristol-Myers Squibb Company (BMY)'s Outlook To Stable; Affirms IDR At "A-" 12/12/2014 9:52:40 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM
Bristol-Myers Squibb Company (BMY) Release: Anticoagulant Effect Of Eliquis (Apixaban) Reversed By Two Separate 4-Factor Prothrombin Complex Concentrates In Healthy Subjects 12/9/2014 11:13:44 AM
Bristol-Myers Squibb Company (BMY) Release: Opdivo (nivolumab) Demonstrates High Overall Response Rate Of 87% for Treatment Of Relapsed Or Refractory Hodgkin Lymphoma 12/8/2014 2:38:44 PM
FDA Requires Additional Data On Bristol-Myers Squibb Company (BMY)' Hep C Daclatasvir 11/26/2014 11:26:36 AM
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) And Prevention Of Recurrent DVT And PE 11/26/2014 10:57:24 AM
Bristol-Myers Squibb Company (BMY) Release: Analyses From Phase 3b Study Provide Additional Data In Earlier Use Of Orencia (Abatacept) Plus Methotrexate (MTX) In Citrullinated Protein (CCP)-Positive Adult Patients With Early Rheumatoid Arthritis (RA) 11/17/2014 12:54:55 PM
Bristol-Myers Squibb Company (BMY) Release: Study Comparing Opdivo (Nivolumab) To Chemotherapy In Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor To Demonstrate A Survival Benefit In A Phase 3 Trial 11/17/2014 11:55:24 AM
Bristol-Myers Squibb Foundation Awards $2 Million In New Grants To Help Veterans And Their Families Transition From Military To Civilian Life 11/10/2014 10:43:59 AM
Bristol-Myers Squibb Company (BMY) Release: ALLY Trial Demonstrates High Cure Rates For Investigational Daclatasvir And Sofosbuvir Combination Among Genotype 3 Hepatitis C Patients 11/10/2014 9:48:34 AM
12345678910...